Indolent Non-Hodgkin Lymphoma Market Set to Witness Steady Growth Through 2036, Driven by Bispecific Antibodies and CAR-T Expansion Across 8MM, Thelansis Reports

Thelansis' market intelligence report examines the evolving iNHL treatment paradigm, emerging pipeline, epidemiology trends, and commercial outlook across the US, EU4, UK, Japan, and China (8MM) for the 2026-2036 forecast period.

The treatment landscape for Indolent Non-Hodgkin Lymphoma (iNHL), encompassing follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM), is undergoing one of its most active transformations in years. With a wave of bispecific antibodies, CAR-T therapies, and next-generation combination regimens reshaping the relapsed/refractory setting, the iNHL market is positioned for sustained value growth over the next decade.

A newly published report, Indolent Non-Hodgkin Lymphoma (iNHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast (2026-2036), offers a comprehensive, data-backed view of this shifting landscape across the eight major markets: the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and China.

Request a free sample of Thelansis' Indolent Non-Hodgkin Lymphoma (iNHL) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/indolent-non-hodgkin-lymphoma-nhl-market-outlook-forecast/

Executive Summary

• Follicular lymphoma remains the most prevalent iNHL subtype, accounting for roughly 20-30% of all non-Hodgkin lymphoma cases diagnosed worldwide each year
• The FL segment alone across major markets is projected to expand from approximately USD 1.7 billion in 2025 to over USD 3 billion by the mid-2030s, reflecting a healthy mid-to-high single-digit CAGR
• Regulatory momentum has accelerated sharply in the last 12 months, with new bispecific antibody approvals and label expansions moving these agents from later lines into earlier, more central roles in FL management
• China and broader Asia-Pacific markets are emerging as the fastest-growing regional contributors, supported by expanding diagnostic infrastructure and improving access to novel immunotherapies
• The report maps out how CAR-T therapies, bispecific antibodies, and oral targeted agents are collectively redefining the treatment sequence, and what this means for market share among established and emerging players through 2036

Key Emerging Players

The iNHL pipeline has become notably crowded, with dozens of sponsors advancing differentiated mechanisms of action. Some of the names reshaping the competitive map include:

• Genmab / AbbVie - epcoritamab (Epkinly), a subcutaneous CD20xCD3 bispecific antibody now approved both as monotherapy and in combination with lenalidomide plus rituximab for relapsed/refractory FL
• Regeneron - odronextamab, a CD20xCD3 bispecific already approved in Europe for relapsed/refractory FL and DLBCL, with a resubmitted US filing under review
• Genentech/Roche - mosunetuzumab (Lunsumio), an established CD20xCD3 bispecific option for heavily pretreated FL patients
• Gilead/Kite - axicabtagene ciloleucel (Yescarta), a CAR-T therapy approved in third-line-plus FL
• Bristol Myers Squibb- lisocabtagene maraleucel (Breyanzi), a CAR-T option with strong response data in relapsed FL
• AstraZeneca - AZD0486, a next-generation CD19xCD3 bispecific in late-stage development for FL
• MorphoSys/Incyte - tafasitamab (Monjuvi) in combination regimens under evaluation for relapsed/refractory FL
• A broader field of 70+ sponsors is running active indolent lymphoma programs spanning bispecifics, cellular therapies, and small-molecule combinations, according to industry pipeline trackers

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Indolent Non-Hodgkin Lymphoma: https://thelansis.com/reports/indolent-non-hodgkin-lymphoma-nhl-market-outlook-forecast/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=inhl_mo

Key Current Therapies or Standard of Care

• First-line management for most FL patients continues to center on anti-CD20 antibody combinations, rituximab or obinutuzumab paired with chemotherapy, followed by watchful waiting for asymptomatic, low-tumor-burden patients
• Obinutuzumab (Gazyva) plus bendamustine remains a well-established option in the relapsed setting, backed by long-standing survival data versus chemotherapy alone
• Tazemetostat (Tazverik), an EZH2 inhibitor, continues to serve as an oral option for select relapsed/refractory FL patients
• CAR-T therapies have secured a firm place in third-line-plus disease, with strong overall response rates reported in pivotal trials
• The newest and fastest-moving development is the entry of bispecific antibodies into earlier treatment lines, epcoritamab combined with lenalidomide and rituximab recently demonstrated a substantial reduction in the risk of disease progression or death compared with lenalidomide and rituximab alone, positioning this class as a genuine second-line contender rather than a last resort
• Watch-and-wait remains clinically appropriate for a meaningful share of asymptomatic patients, underscoring the chronic, manageable nature of iNHL relative to aggressive lymphomas

Key Market Drivers/Trends

• Bispecific antibodies moving earlier in the treatment sequence - regulatory decisions over the past year have expanded bispecific use beyond salvage therapy into second-line combination regimens, a structural shift expected to influence prescribing patterns industry-wide
• Maturing CAR-T data in indolent disease - durable response data from pivotal CAR-T trials in FL continue to support broader clinical adoption and payer acceptance
• Fixed-duration and subcutaneous formulations gaining favor- shorter administration times and defined treatment courses are improving convenience for both patients and infusion centers
• Rising diagnosed prevalence - an aging population, improved diagnostic pathways, and greater disease awareness are expanding the treated patient pool across all 8 major markets
• China's accelerating role - regulatory reform and expanding oncology infrastructure are positioning China as one of the fastest-growing markets for novel lymphoma therapies within the 8MM cohort
• Pipeline depth beyond FL- emerging interest in marginal zone lymphoma and Waldenström macroglobulinemia is broadening the addressable iNHL opportunity beyond follicular lymphoma alone

Translate these macro drivers into a competitive advantage. Request the Thelansis Indolent Non-Hodgkin Lymphoma (iNHL) sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/indolent-non-hodgkin-lymphoma-nhl-market-outlook-forecast/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=inhl_mo

Key Unmet Need & KOL Expectations
• Despite recent progress, iNHL remains largely incurable with standard approaches, most patients still experience relapse over time, keeping long-term disease control a central treatment goal rather than cure
• Hematology-oncology experts continue to flag the need for better sequencing strategies as more mechanism classes: CAR-T, bispecifics, and oral targeted agents, compete for the same treatment lines
• There is growing clinical interest in identifying biomarkers, such as minimal residual disease status, to guide treatment selection and de-escalation
• KOLs expect the next wave of trials to test bispecific-based combinations in earlier, potentially frontline settings, a shift that could meaningfully alter the current treatment paradigm if confirmed in ongoing phase 3 studies
• Community oncology access to newer cellular and bispecific therapies remains a practical gap that experts expect to narrow as subcutaneous and outpatient-friendly regimens expand

Commercial Opportunity
• The convergence of new mechanism classes and expanding regulatory approvals creates a genuine window for both established players and emerging biotechs to capture share in a market that is still actively being redefined
• Companies with differentiated bispecific or cellular therapy assets are well positioned to benefit as earlier-line adoption accelerates over the forecast period
• China and the broader Asia-Pacific region represent an outsized growth opportunity relative to the more mature US and EU5 markets
• Licensing, co-development, and geographic expansion deals are likely to increase as sponsors look to maximize commercial reach across all 8 major markets
• The report provides a full quantitative breakdown of market size, growth trajectory, and competitive positioning to support strategic planning, licensing evaluation, and investment decision-making through 2036

About the Report
This report delivers an in-depth, data-driven assessment of the iNHL treatment and market landscape across the US, Germany, France, Italy, Spain, the UK, Japan, and China. It includes historical and forecasted epidemiology, a detailed review of current and emerging therapies, competitive landscape mapping, and a 2026-2036 market forecast - built to support pharmaceutical and biotech decision-makers in commercial strategy, licensing, and portfolio planning.

Access the complete Indolent Non-Hodgkin Lymphoma (iNHL) market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/indolent-non-hodgkin-lymphoma-nhl-market-outlook-forecast/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=inhl_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.